Aytu BioPharma (NASDAQ:AYTU) Price Target Cut to $6.00

Aytu BioPharma (NASDAQ:AYTUGet Rating) had its price target reduced by investment analysts at HC Wainwright from $11.00 to $6.00 in a report issued on Thursday, The Fly reports. The firm presently has a “buy” rating on the stock.

Separately, Cantor Fitzgerald lowered their target price on shares of Aytu BioPharma from $11.00 to $5.00 in a report on Tuesday, May 17th.

Aytu BioPharma Stock Performance

AYTU stock opened at $0.57 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.97 and a quick ratio of 0.80. The company has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.90. Aytu BioPharma has a fifty-two week low of $0.45 and a fifty-two week high of $4.21. The stock has a market capitalization of $21.91 million, a PE ratio of -0.14 and a beta of -0.34.

Aytu BioPharma (NASDAQ:AYTUGet Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.14. Aytu BioPharma had a negative net margin of 120.24% and a negative return on equity of 41.97%. The firm had revenue of $24.20 million during the quarter, compared to analysts’ expectations of $24.20 million. Analysts forecast that Aytu BioPharma will post -1.34 EPS for the current year.

Hedge Funds Weigh In On Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Renaissance Technologies LLC grew its position in Aytu BioPharma, Inc. (NASDAQ:AYTUGet Rating) by 15.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 765,469 shares of the company’s stock after buying an additional 100,400 shares during the period. Renaissance Technologies LLC owned approximately 2.29% of Aytu BioPharma worth $827,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.47% of the company’s stock.

About Aytu BioPharma

(Get Rating)

Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.

Recommended Stories

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.